Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding

Venue: Sheraton National Hotel Arlington

Location: Arlington, Virginia, United States

Event Date/Time: Apr 11, 2010 End Date/Time: Apr 13, 2010
Report as Spam


Abstract Submission Guidelines

Please submit all abstracts via email to Rachel Minnick, Program Developer

All abstracts must be received by February 13, 2010

Authors of selected abstracts will be notified by March 13, 2010

Suggested Abstract Topics

(The strongest abstracts have been those with a clear hypothesis and supporting data with a strong scientific design)

Drug Development and CV safety

· Drug-induced increases in CV events

· Myocardial toxicity

· Pharmacogenomics and drug-induced CV injury

· How can we practically assess the negative inotropic potential of new drugs?

· Anticoagulant safety—how to measure it?

Evolving Science of QT/Arrhythmia Assessment